Exclusive Interviews

In part 2 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the standings of the oral GLP-1 drug and their work on another oral drug.

In part 3 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the results of the SUSTAIN-7 trial and their implications for diabetes patients.

In part 4 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the benefits of both an SGLT-2 and GLP-1 injectable, as found in the Dual 9 study.

In part 5 of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the overall results of the Confirm real-world study.

In part 6, the conclusion of this Exclusive Interview, Todd Hobbs talks with Diabetes in Control Publisher Steve Freed about the upcoming focus on treating obesity as well as an oral form of semaglutide.

Rachele Berria MD, PhD is Vice President and Head, Diabetes Medical Unit at Sanofi, Bridgewater, New Jersey. She has a medical degree (undergrad/graduate combined program) and Obstetrics and Gynecology Board Certification from the University of Cagliari School of Medicine, Italy. Her many other educational accomplishments include a Master of Science in Clinical Investigation from the University of Texas Health Science Center at San Antonio, Texas; Ph.D. Degree in Medical Pathophysiology and Pharmacology from the University of Pisa School of Medicine, Italy; a Fellowship in Diabetes and Metabolism from the Internal Medicine Department, University of Texas Health Science Center at San Antonio, Texas;  and a Master Practitioner Certification in Effective Communication from the Neurolinguistic Programming Center of New York City, NY.

In this Exclusive Interview transcript, Rachele Berria talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of studies such as the head-to-head trial of two long-acting basal insulins, and what Sanofi has in the pipeline.

In this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about the results of studies such as the head-to-head trial of two long-acting basal insulins.

In part 1 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the various trials of interest presented at the conference, such as the latest regarding the study of two basal insulins.

In part 2 of this Exclusive Interview, Rachele Berria talks with Diabetes in Control Publisher Steve Freed about the products in the works at Sanofi.